Envoy MedicalCOCH +7.24%24 EBITDA Margin % is -10,969.23% as of Mar. 2026. GuruFocus rates COCH with a GF Score™ of 24/100 and a GF Value™ of $1.14 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Envoy Medical ranks worse than 98.53% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Envoy Medical's EBITDA for the
three
months ended in Mar. 2026 was $-4.28 Mil. Envoy Medical's Revenue for the
three
months ended in Mar. 2026 was $0.04 Mil. Therefore, Envoy Medical's EBITDA margin for the quarter that ended in Mar. 2026 was -10,969.23%.
Envoy Medical (NAS:COCH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Envoy Medical EBITDA Margin % Related Terms
Envoy Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Envoy Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COCH vs ELUT, SRTS, BDMD: EBITDA Margin % Comparison
For the Medical Devices subindustry, Envoy Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Envoy Medical EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Envoy Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Envoy Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envoy Medical (COCH) has a EBITDA Margin % of -10,969.23% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Envoy Medical and its competitors. According to the industry distribution chart, Envoy Medical ranks #804 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 98.5%.
Is Envoy Medical's EBITDA Margin % too high?
Envoy Medical's current EBITDA Margin % is -10,969.23%. Based on the distribution chart, Envoy Medical ranks #804 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Envoy Medical has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Envoy Medical's EBITDA Margin % compare to ELUT and SRTS?
According to the Medical Devices & Instruments industry distribution chart, Envoy Medical ranks #804 out of 816 companies for EBITDA Margin %. This places Envoy Medical in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Envoy Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envoy Medical's current EBITDA Margin % is -10,969.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envoy Medical stock overvalued right now?
Based on GuruFocus' analysis, Envoy Medical (COCH) is currently considered Possible Value Trap. The stock's GF Value™ is $1.14, compared to a current price of $0.68 — trading 40.3% below its estimated fair value. The current EBITDA Margin % is -10,969.23%. Envoy Medical's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Envoy Medical (COCH), the current EBITDA Margin % is -10,969.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envoy Medical (COCH) Overvalued in 2026?
Based on GuruFocus' analysis, Envoy Medical stock appears to be undervalued.
The current stock price of $0.68 is trading 40.3% below its estimated GF Value™ of $1.14.
GuruFocus considers Envoy Medical to be Possible Value Trap.
Key valuation signals for COCH:
EBITDA Margin %: -10,969.23%
GF Value™: $1.14 vs. price of $0.68 (40.3% below fair value)
No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
24GF Score
Get the complete analysis for COCH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCH has been successfully added to your 
